Daily treatment with IPL344 for up to three years was safe and slowed ALS progression in a small Phase 2a clinical trial, ...

Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages ...